<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: <z:e sem="disease" ids="C0276653" disease_type="Disease or Syndrome" abbrv="">Invasive pulmonary aspergillosis</z:e> (IA) is the most frequent invasive <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">fungal infection</z:e> in patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Massive <z:hpo ids='HP_0002105'>hemoptysis</z:hpo> (MH) with blood loss more than 300-600 ml in 24 hours is a rare (5-10% of IA patients) but frequently fatal complication </plain></SENT>
<SENT sid="2" pm="."><plain>Standard treatment of MH, such as oxygenation, a semi-sitting position with the <z:mp ids='MP_0001914'>bleeding</z:mp> site down, bronchoscopical suctioning, antifungal therapy, transfusion support and surgical resection might be either ineffective or not feasible in some cases </plain></SENT>
<SENT sid="3" pm="."><plain>OUTLINE OF CASES: We report two patients with life threatening, non-controlled, massive <z:hpo ids='HP_0002105'>hemoptysis</z:hpo> who were successfully managed by non-standard measures </plain></SENT>
<SENT sid="4" pm="."><plain>A 61-year-old male with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> developed pulmonary IA and massive <z:hpo ids='HP_0002105'>hemoptysis</z:hpo> after consolidation cure by chemotherapy </plain></SENT>
<SENT sid="5" pm="."><plain>The <z:mp ids='MP_0001914'>bleeding</z:mp> site was localized in the VI lung segment by bronchoscopy </plain></SENT>
<SENT sid="6" pm="."><plain>Local application of fibrinogen-thrombin concentrate (fibrin glue) stopped the <z:mp ids='MP_0001914'>bleeding</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>A 22-year-old female patient with the diagnosis of severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> developed IA and massive <z:hpo ids='HP_0002105'>hemoptysis</z:hpo> early after application of immunosuppressive therapy (antilymphocyte globulin, <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> and <z:chebi fb="0" ids="50858">corticosteroids</z:chebi>) </plain></SENT>
<SENT sid="8" pm="."><plain>Conventional transfusion therapy, desmopresine and antifibrinolytics were ineffective </plain></SENT>
<SENT sid="9" pm="."><plain>This urgent condition was successfully treated with human activated recombinant factor VII (rFVIIa, NovoSeven) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: Our experience together with data from the available literature suggests a potential benefit of fibrinogen-thrombin concentrate and rFVIIa in the treatment of refractory critical <z:mp ids='MP_0001914'>bleeding</z:mp> in hemato-oncological patients </plain></SENT>
</text></document>